Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mutant of human papilloma virus 39 type L1 protein

A protein and variant technology, applied in the fields of molecular virology and immunology, can solve problems such as safety issues and increased production costs of HPV vaccines

Pending Publication Date: 2019-12-10
XIAMEN UNIV +1
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this approach will lead to a substantial increase in the production cost of the HPV vaccine, and may cause potential safety issues due to the increased dose of immunization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mutant of human papilloma virus 39 type L1 protein
  • Mutant of human papilloma virus 39 type L1 protein
  • Mutant of human papilloma virus 39 type L1 protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0165] Example 1. Expression and purification of mutant HPV39 L1 protein

[0166] Construction of expression vector

[0167] A multi-point mutation PCR reaction was used to construct an expression vector encoding a mutant HPV39L1 protein containing a segment derived from the HPV68L1 protein. The initial template used was the pTO-T7-HPV39N15C plasmid (which encodes 15 truncated N-terminals). HPV39 L1 protein of amino acids; abbreviated as 39 L1N15 in Table 2). The templates and primers used in each PCR reaction are shown in Table 2, and the amplification conditions of the PCR reaction are set to: denaturation at 94°C for 10 minutes; 25 cycles (denaturation at 94°C for 50 seconds, annealing at specified temperature for a certain time, extension at 72°C 7 minutes 30 seconds); the final extension at 72°C for 10 minutes. The annealing temperature and time are listed in Table 2. The specific sequences of the PCR primers used are listed in Table 3.

[0168] Add 2 μL of DpnI restriction...

Embodiment 2

[0195] Example 2: Assembly of HPV virus-like particles and particle morphology detection

[0196] Assembly of HPV virus-like particles

[0197] Take a certain volume (about 2ml) of protein H39N15-68T1, H39N15-68T2, H39N15-68T3, H39N15-68T4, H39N15-68T5, H39N15-68T4-70S1, H39N15-68T4-70S2, H39N15-68T4-70S3 and H39N15-68T4-70S68 -70S5, respectively dialyzed to (1) 2L storage buffer (20mM sodium phosphate buffer pH 6.5, 0.5M NaCl); (2) 2L refolding buffer (50mM sodium phosphate buffer pH 6.0, 2mM CaCl) 2 , 2mM MgCl 2 , 0.5M NaCl); and (3) 20mM sodium phosphate buffer pH 7.0, 0.5M NaCl. Dialysis was performed in each of the three buffers for 12 h.

[0198] In a similar way, HPV39N15, HPV68N0 and HPV70N10 proteins were assembled into HPV39N15VLP, HPV68N0 VLP and HPV70N10 VLP, respectively.

[0199] Molecular Sieve Chromatography Analysis

[0200] Molecular sieve chromatography was performed on the dialyzed samples with the 1120Compact LC high performance liquid chromatography system of A...

Embodiment 3

[0205] Example 3: Evaluation of neutralizing antibody titer in mouse serum after immunization with virus-like particles 1

[0206] In this experiment, the virus-like particles used are: H39N15-68T1 VLP, H39N15-68T2 VLP, H39N15-68T3VLP, H39N15-68T4 VLP and H39N15-68T5 VLP.

[0207] In this experiment, the immunization scheme is shown in Table 4. Divide all mice (6-week-old BalB / c female mice) into 3 groups: aluminum adjuvant group 1 (immunization dose is 5μg, using aluminum adjuvant), aluminum adjuvant group 2 (immunization dose is 1μg, using aluminum adjuvant) Aluminum adjuvant), and aluminum adjuvant group 3 (immunization dose is 0.2 μg, using aluminum adjuvant). Each group was subdivided into 8 subgroups. Control subgroups 1 and 2 were immunized with HPV39N15 VLP alone and HPV68N0 VLP alone, and control subgroup 3 was immunized with mixed HPV39 / HPV68VLP (ie, HPV39N15 VLP and HPV68N0 VLP). A mixture in which each VLP is administered at a specified immunizing dose) for immunizati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
radiusaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a mutant HPV 39 L1 protein (or a mutant thereof), a coding sequence and a preparation method thereof, and a virus-like particle comprising HPV. The protein (or the mutant thereof) can induce neutralizing antibodies against at least two types of HPVs (e.g., HPV 39 and HPV 68, or HPV 39, HPV 68 and HPV 70), thereby being used for preventing infections by the at leasttwo types of the HPVs and diseases caused by the infections, such as cervical cancer and condyloma acuminatum. The present invention also relates to uses of the protein and virus-like particle for preparation of drug compositions or vaccines, the drug compositions or vaccines can be used for preventing at least two types of the HPV infections and diseases caused by the infections, such as the cervical cancer and condyloma acuminatum.

Description

[0001] This application is based on the application with the CN application number 201810563378.0 and the filing date of June 4, 2018, and claims its priority. The disclosure of the CN application is hereby incorporated into this application as a whole. Technical field [0002] The invention relates to the fields of molecular virology and immunology. Specifically, the present invention relates to a mutant HPV39 L1 protein (or its variants), its coding sequence and preparation method, and virus-like particles comprising it, the protein (or its variants) and virus-like particles can induce Neutralizing antibodies against at least two types of HPV (for example, HPV39 and HPV68, or HPV39, HPV68, and HPV70), which can be used to prevent the at least two types of HPV infection and diseases caused by the infection Such as cervical cancer and condyloma acuminatum. The present invention also relates to the use of the above-mentioned protein and virus-like particles for preparing pharmace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/025C12N15/37A61K39/12A61P31/20A61P35/00
CPCC07K14/005A61K39/12A61P31/20A61P35/00C12N2710/20022C12N2710/20023C12N2710/20034C12N2710/20071A61K2039/5258A61K2039/53C12N7/00C07K14/025C12N15/70
Inventor 李少伟王大宁王致萍柳欣林张军夏宁邵
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com